is glutathione a tyrosinase inhibitor comprehensive review on inhibitors Determination of tyrosinase-cyanidin-3-O-glucoside and (−/+)-catechin

If you see something that implies BPC-157 or any unapproved peptide is clinically backed or approved, take it down and have legal and clinical experts review your copy before updating

It's important to note that despite these promising animal study results, the lack of robust human data presents a significant caveat

Metabolite profiling reveals that the most frequently-occurred BRAF mutation endows melanoma cells with enhanced glycolytic capacity, which can be attributed to the upregulation of a network of transcriptional factors, glucose transporters, and kinases controlling glycolysis including HIF1, MYC, Glut 1, Glut 3, and Hexokinase 2 (HK2)

Share this article

Foote SL, Berridge CW

2020 Mar;6(2):284-287